Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 20;12(3):459.
doi: 10.3390/life12030459.

When Nothing Goes Right: Risk Factors and Biomarkers of Right Heart Failure after Left Ventricular Assist Device Implantation

Thomas Schlöglhofer  1   2   3 , Franziska Wittmann  1 , Robert Paus  1   3 , Julia Riebandt  1 , Anne-Kristin Schaefer  1 , Philipp Angleitner  1 , Marcus Granegger  1 , Philipp Aigner  2   3 , Dominik Wiedemann  1 , Günther Laufer  1 , Heinrich Schima  1   2   3 , Daniel Zimpfer  1   2
Affiliations

When Nothing Goes Right: Risk Factors and Biomarkers of Right Heart Failure after Left Ventricular Assist Device Implantation

Thomas Schlöglhofer et al. Life (Basel). .

Abstract

Right heart failure (RHF) is a severe complication after left ventricular assist device (LVAD) implantation. The aim of this study was to analyze the incidence, risk factors, and biomarkers for late RHF including the possible superiority of the device and implantation method. This retrospective, single-center study included patients who underwent LVAD implantation between 2014 and 2018. Primary outcome was freedom from RHF over one-year after LVAD implantation; secondary outcomes included pre- and postoperative risk factors and biomarkers for RHF. Of the 145 consecutive patients (HeartMate 3/HVAD: n = 70/75; female: 13.8%), thirty-one patients (21.4%) suffered RHF after a mean LVAD support of median (IQR) 105 (118) days. LVAD implantation method (less invasive: 46.7% vs. 35.1%, p = 0.29) did not differ significantly in patients with or without RHF, whereas the incidence of RHF was lower in HeartMate 3 vs. HVAD patients (12.9% vs. 29.3%, p = 0.016). Multivariate Cox proportional hazard analysis identified HVAD (HR 4.61, 95% CI 1.12-18.98; p = 0.03), early post-op heart rate (HR 0.96, 95% CI 0.93-0.99; p = 0.02), and central venous pressure (CVP) (HR 1.21, 95% CI 1.05-1.39; p = 0.01) as independent risk factors for RHF, but no association of RHF with increased all-cause mortality (HR 1.00, 95% CI 0.99-1.01; p = 0.50) was found. To conclude, HVAD use, lower heart rate, and higher CVP early post-op were independent risk factors for RHF following LVAD implantation.

Keywords: mechanical circulatory support; right heart failure; risk factor; ventricular assist device.

PubMed Disclaimer

Conflict of interest statement

T.S. has served as a consultant and advisor for Medtronic Inc. and Abbott Inc., and has received research grants from Medtronic Inc., Abbott Inc., and CorWave. M.G. has served as a consultant for Berlin Heart. H.S. has served as an advisor for Medtronic Inc. and has received research grants from Medtronic Inc. D.W. has served as a proctor and consultant for Abbott Inc. and has served as an advisor for Xenios/Fresenius Medical Care. D.Z. has served as a proctor, advisor, and speaker for Medtronic Inc., Abbott Inc., Berlin Heart, Edwards, Abiomed, and has received research and travel grants from Medtronic Inc. and Abbott Inc. All other authors have nothing to disclose.

Figures

Figure 1
Figure 1
Patient flow chart. Of n = 179 consecutive VAD patients, n = 145 met all inclusion criteria and were included in the study cohort.
Figure 2
Figure 2
Baseline demographics including intraoperative variables, comorbidities, and preoperative laboratory and hemodynamic parameters of freedom from right heart failure one-year following LVAD implantation (A) and stratified by device type (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V.-P., Jankowska E.A., et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur. Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed
    1. Lima B., Mack M., Gonzalez-Stawinski G.V. Ventricular assist devices: The future is now. Trends Cardiovasc. Med. 2015;25:360–369. doi: 10.1016/j.tcm.2014.11.008. - DOI - PubMed
    1. Ranganath N.K., Smith D.E., Moazami N. The Achilles’ heel of left ventricular assist device therapy: Right ventricle. Curr. Opin. Organ Transplan. 2018;23:295–300. doi: 10.1097/MOT.0000000000000528. - DOI - PubMed
    1. Lampert B.C., Teuteberg J.J. Right ventricular failure after left ventricular assist devices. J. Heart Lung Transp. 2015;34:1123–1130. doi: 10.1016/j.healun.2015.06.015. - DOI - PubMed
    1. Dandel M., Krabatsch T., Falk V. Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. Int. J. Cardiol. 2015;198:241–250. doi: 10.1016/j.ijcard.2015.06.103. - DOI - PubMed

LinkOut - more resources